Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis Neoadjuvant HER2+Colorectal Cancer Interactive Tools

Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma

Insights Medical World News News Network OncLive TV Peer Exchange Podcasts Rapid Readouts The Talk

Giants of Cancer Care OncLive Events Scientific Interchange Workshop Series PER Events State of the Science Summit / IPC Webinars

CME Community Interactive Tools Partners

Advertise
News
About OncLive
Editorial Board
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2020 MJH Life Sciences and OncLive. All rights reserved.

Spotlight

Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis
Neoadjuvant HER2+
Colorectal Cancer
Interactive Tools

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

OncLive SOSS

Advertise
News
About OncLive
Editorial Board
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2020 MJH Life Sciences^™ and OncLive. All rights reserved.

Rapid Readouts: Initial Results of the Phase III BOSTON Study

June 29, 2020

Cristina Gasparetto, MD, Duke Cancer Institute

x